news慢性淋巴细胞白血病，免疫球蛋白水平，单克隆 B 细胞淋巴细胞增多症，癌症易感性Ianalumab
Adding Ianalumab to Ibrutinib Induces Deep Remissions and Enables Therapy Discontinuation in Chronic Lymphocytic Leukemia
By MedXY|Jan 13, 2026
A Phase Ib study reveals that adding the anti-BAFF-R antibody ianalumab to ibrutinib therapy achieves high rates of undetectable measurable residual disease (uMRD), allowing over 40% of CLL patients to successfully discontinue long-term tre
